Description
Bortezomib (Bortenat) injection belongs to a group of medicines known as proteasome inhibitors (PIs). It is an antineoplastic agent supplied for intravenous injection (IV) or subcutaneous use (SC). Bortezomib injection is approved for the treatment of adult patients with multiple myeloma (MM) and mantle cell lymphoma (MCL).
Dosage and Side Effects of Bortezomib Injection:
The recommended initial dose of Bortezomib Injection is 1.3 mg/m2 administered as a 3-5 second bolus intravenous (IV) injection. Dosage administered intravenously (IV) at a concentration of 1 mg/mL or 2.5 mg/mL. Retreatment with Bortenat injection may be considered for patients with multiple myeloma (MM) who had earlier responded to therapy with bortezomib injections and who have relapsed at least six months after completing prior bortezomib therapy. Treatment may be initiated at the final tolerated dose.Â
The most common side effects of Bortezomib injection are vomiting, leukopenia, thrombocytopenia, neutropenia, diarrhea, peripheral neuropathy, fatigue, neuralgia, anemia, constipation, lymphopenia, nausea, pyrexia, rash, and anorexia
Warning and Precautions of Bortezomib Injection:
- This medicine causes a peripheral neuropathy that is predominantly sensory; however, cases of serious sensory and motor peripheral neuropathy may develop. Individuals experiencing new or worsening peripheral neuropathy during treatment may require a reduction in the dose and/or a less dose-intense schedule.
- Events of hypotension (orthostatic, postural, and hypotension NOS) may occur during treatment. Those with a previous history of syncope, patients receiving medicines known to be linked with hypotension, and patients who are dehydrated may be at increased risk of hypotension. Adjust antihypertensive drugs, hydration, and administer mineralocorticoids and/or sympathomimetics.
- Acute Respiratory Distress Syndrome (ARDS) and acute diffuse infiltrative pulmonary disease of unknown etiology such as pneumonitis, interstitial pneumonia, and lung infiltration may occur in all those receiving Bortenat 3.5mg/2mg injection. Some of these events have been fatal. In the event of any new or worsening cardiopulmonary signs and symptoms, interrupt treatment until a quick and complete diagnostic assessment is conducted.
- PRES; formerly known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS) may occur in patients receiving treatment with Bortenat. Magnetic Resonance Imaging (MRI), is used for the confirmation of the diagnosis. In those developing PRES, stop bortezomib treatment.
- Treatment with bortezomib can be responsible for nausea, constipation, diarrhea, and vomiting sometimes requiring the use of antidiarrheal and antiemetic drugs. Ileus can occur. Administer fluid and electrolyte replacement to prevent dehydration. Interrupt this treatment for any critical symptom.
- Bortezomib 2mg/3.5mg can be responsible for causing neutropenia and thrombocytopenia that follow a cyclical pattern with nadirs occurring after the final dose of each cycle and typically recovering before initiating the subsequent cycle. Monitor CBC frequently throughout treatment. Platelet counts need to be measured before each dose.
- Tumor lysis syndrome (TLS) may occur with Bortenat injection treatment. Patients at risk of tumor lysis syndrome (TLS) are those with high tumor burden before treatment. Monitor patients Precisely and consider relevant precautions.
- Mechanism of action and findings suggest that Bortenat injection can cause fetal harm when used by a pregnant woman. Due to the potential for serious side effects in a breastfed child from medicine, advise nursing women to avoid breastfeeding during treatment and for 2 months after therapy.Â